BioSpace News Archive

Emerald Health Therapeutics, Inc. announces that it intends to amend the terms of certain common share purchase warrants originally issued on September 9, 2019..

MBio Diagnostics announced an expanded scope contract with the US Defense Advanced Research Projects Agency, where DARPA will apply additional resources and funds to accelerate progress towards FDA approval for MBio’s LightDeck® platform.

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”) today announced that it has completed its previously announced redemption all of its outstanding 15% unsecured debentures issued November 8, 2019 (the “Debentures”) at a price equal to 110% of the principal amount of the Debentures (the “Redemption Price”).

Several media reports of cases of pulmonary fibrosis resulting from COVID-19 disease have raised important questions in the pulmonary fibrosis community.

Prisma Health announced that it is collaborating with Ethicon Inc., part of the Johnson & Johnson Medical Devices Companies, to make and distribute a ventilator expansion device, called the VESper™ Ventilator Expansion Splitter.

America’s Blood Centers and its members are working closely with the U.S. Food and Drug Administration to collect and distribute convalescent plasma from individuals who have recovered from COVID-19..

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

Golfers Against Cancer takes pride in identifying research projects dedicated to specific work targeting various forms of cancer.

ReNeuron Group plc, a global leader in the development of cell-based therapeutics, provides the following update in light of the COVID-19 pandemic and the effect on the Company of U.K. and U.S. government measures to contain the spread of the disease..

Invitae Corporation announced the closing of its underwritten public offering of 20,444,444 shares of its common stock, including 2,666,666 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at the public offering price of $9.00 per share.